Together, the priority studies require patient enrollment of nearly 43,500. To date, about 17,400 patients have been enrolled, leaving more than 26,000 patients still needed for these studies. Enrollment of breast cancer patients in publicly funded studies averages about 9,300 annuallyi; the number of breast cancer patients on privately funded studies is not known. More rapid enrollment and timely completion of these studies can quicken the pace of diagnostic and treatment advances by resolving clinical questions such as:

  • How to predict the impact of biological effects of chemopreventive agents with the development and validation of new, clinically relevant biomarkers
  • How to design, select – and afford - individualized cancer therapy in an era of escalating costs for biologic treatments
  • How, when and whether to use chemotherapy in breast cancer treatment for some patients
  • How to best incorporate novel approaches, including biophosphonates in breast cancer treatment to reduce the risk of bone metastases
  • How best to address the growing issue of long term neurotoxic and cognitive side effects in breast cancer survivors
  • How to design clinical trials that can be completed more efficiently including randomized discontinuation trials or "adaptive" trial designs that require fewer patients and/or shorter study duration.